HIV-1 Envelope, Group-specific antigen, and Polymerase antigens (encoded by MVA-CMDR) (HIV-1 Env/Gag/Pol (MVA-CMDR))

The HIV-1 Env, Gag, and Pol antigens encoded by MVA-CMDR represent a specific set of viral proteins used in recombinant vaccine candidates to prevent or treat HIV-1 infection (PubMed: 17932234). MVA-CMDR is a Modified Vaccinia Ankara vector engineered to express the envelope (Env), group-specific antigen (Gag), and polymerase (Pol) proteins derived from the HIV-1 CRF01_AE subtype, which is prevalent in Southeast Asia (NIH). The Env protein is responsible for viral attachment and entry into host cells, while Gag provides the structural framework for the virus, and Pol encodes essential enzymes for replication (UniProt). When delivered via the MVA vector, these antigens are expressed in host cells, triggering both humoral and cellular immune responses (PubMed: 22933714). This approach aims to train the immune system to recognize and eliminate HIV-infected cells or prevent initial infection. Clinical studies, particularly in Thailand, have evaluated MVA-CMDR as part of prime-boost strategies to enhance the breadth and durability of the immune response against HIV-1 (ClinicalTrials.gov).

Other names

MVA-CMDRModified Vaccinia Ankara-Chiang Mai Double RecombinantHIV-1 CRF01_AE Env/Gag/Pol antigensMVA-HIV-1 (Env/Gag/Pol)

Active immunization inducing HIV-1 specific cellular (CD4+ and CD8+ T-cell) and humoral immune responses through the expression of viral antigens by a non-replicating viral vector (PubMed: 17932234).